Cutera Inc. (NASDAQ:CUTR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “

Cutera (NASDAQ:CUTR) opened at 14.00 on Wednesday. Cutera has a 12 month low of $9.83 and a 12 month high of $14.95. The stock’s 50 day moving average is $13.20 and its 200-day moving average is $11.49. The stock’s market capitalization is $183.25 million.

Cutera (NASDAQ:CUTR) last issued its earnings results on Monday, November 7th. The medical device company reported $0.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.08. Cutera had a return on equity of 4.90% and a net margin of 0.38%. The business earned $30.30 million during the quarter, compared to analysts’ expectations of $28.84 million. During the same quarter in the previous year, the business earned ($0.07) EPS. The company’s revenue for the quarter was up 31.3% on a year-over-year basis. On average, equities research analysts expect that Cutera will post $0.05 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in CUTR. Rhumbline Advisers boosted its position in Cutera by 7.8% in the second quarter. Rhumbline Advisers now owns 17,006 shares of the medical device company’s stock worth $191,000 after buying an additional 1,235 shares in the last quarter. TFS Capital LLC boosted its position in Cutera by 12.9% in the second quarter. TFS Capital LLC now owns 58,763 shares of the medical device company’s stock worth $659,000 after buying an additional 6,714 shares in the last quarter. Globeflex Capital L P boosted its position in Cutera by 265.6% in the second quarter. Globeflex Capital L P now owns 11,700 shares of the medical device company’s stock worth $131,000 after buying an additional 8,500 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Cutera by 11.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 609,527 shares of the medical device company’s stock worth $6,833,000 after buying an additional 61,028 shares in the last quarter. Finally, BlackRock Investment Management LLC boosted its position in Cutera by 1.3% in the second quarter. BlackRock Investment Management LLC now owns 52,138 shares of the medical device company’s stock worth $584,000 after buying an additional 680 shares in the last quarter. Hedge funds and other institutional investors own 79.51% of the company’s stock.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

5 Day Chart for NASDAQ:CUTR

Receive News & Stock Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related stocks with our FREE daily email newsletter.